Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.
- DOI
- 10.1007/s40120-025-00872-1
- Published
- 2026 Feb
- Container
- Neurology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40120-025-00872-1,
title = {Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.},
author = {Buse DC and Lipton RB and Urman R and Vaidya SJ and Robinson SC and Jacobson AS and Scott AB and Bensink ME and Pressman AR},
year = {2026},
journal = {Neurology and therapy},
doi = {10.1007/s40120-025-00872-1},
url = {https://doi.org/10.1007/s40120-025-00872-1}
}RIS
TY - JOUR TI - Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study. AU - Buse DC AU - Lipton RB AU - Urman R AU - Vaidya SJ AU - Robinson SC AU - Jacobson AS AU - Scott AB AU - Bensink ME AU - Pressman AR PY - 2026 JO - Neurology and therapy DO - 10.1007/s40120-025-00872-1 UR - https://doi.org/10.1007/s40120-025-00872-1 ER -
APA
DC, B., RB, L., R, U., SJ, V., SC, R., AS, J., AB, S., ME, B., & AR, P. (2026). Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.. Neurology and therapy. https://doi.org/10.1007/s40120-025-00872-1
Source records
- pubmed · retrieved 2026-09-27T07:00:48.806Z